The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The bottom line For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

More specifically, 63% of people on semaglutide had resolution of MASH without worsening fibrosis versus 34% on placebo. This means they had less inflammation in the liver, without worse scarring.